SCHEMBL24253578

SCHEMBL24253578

O=C1CCCC2(CCN(c3ccn(-c4ccc(F)cc4)n3)CC2)N1c1ccc(Cl)c(F)c1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.33
UBE2N P61088 2/20 0.33
CYP11B2 P19099 1/20 0.32
RAD51 Q06609 1/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
KCNH2 Q12809 1/20 0.32
LTC4S Q16873 1/20 0.32
FAAH O00519 1/20 0.32
MGLL Q99685 1/20 0.32
MMP13 P45452 1/20 0.31
HTR1A P08908 1/20 0.31
ADRA1A P35348 1/20 0.31
ADRA1B P35368 1/20 0.31
JAK2 O60674 1/20 0.30
TYK2 P29597 1/20 0.30
MAPT P10636 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
ACKR3 P25106 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424099 1.00 KMT2A (0.33) KMT2AUBE2NCYP11B2RAD51HCRTR1
SCHEMBL24253932 0.88 KCNH2 (0.35) CYP11B2RAD51HCRTR1HCRTR2KCNH2
SCHEMBL30424672 0.88 KCNH2 (0.35) CYP11B2RAD51HCRTR1HCRTR2KCNH2
SCHEMBL30424244 0.84 CYP11B2 (0.35) CYP11B2RAD51MMP13
SCHEMBL24253724 0.84 HCRTR1 (0.33) CYP11B2RAD51HCRTR1HCRTR2KCNH2
SCHEMBL30424476 0.84 HCRTR1 (0.33) CYP11B2RAD51HCRTR1HCRTR2KCNH2
SCHEMBL24253617 0.84 CYP11B2 (0.35) CYP11B2RAD51MMP13
SCHEMBL24253716 0.78 HCRTR1 (0.30) HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL30424677 0.78 HCRTR1 (0.30) HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL24253536 0.77 DPP4 (0.36) CYP11B2RAD51HCRTR1HCRTR2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 KMT2A 3399/4885UBE2N 3563/4885CYP11B2 22/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 KMT2A 3399/4885UBE2N 3563/4885CYP11B2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.